IngredientsLeucoanthocyanidins (also formally designated flavan-3,4-diols) are colorless chemical compounds related to anthocyanidins and anthocyanins. The prefix leuco- derives from the Greek for "white" or "colorless," distinguishing them from the intensely pigmented anthocyanin family from which they take their name. In the broader classification of flavonoids, leucoanthocyanidins are categorized as a subgroup of flavanols, specifically within the flavan-3,4-diol subclass, distinguishing them from other flavonoid types such as flavonols, flavones, and anthocyanins based on modifications to the central C3 unit of the flavonoid skeleton.
Common variants include leucocyanidin, leucodelphinidin, and leucopelargonidin, distinguished by the hydroxylation pattern on the B ring, which corresponds to their anthocyanidin derivatives cyanidin, delphinidin, and pelargonidin, respectively. The most studied individual compound within this class is leucocyanidin. Leucocyanidin has the molecular formula C15H14O7 with a molecular weight of 306.27 g/mol. This compound is a type of flavan-3,4-diol that serves as a precursor in anthocyanin biosynthesis. Structurally, leucocyanidin is characterized as 2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,4,5,7-tetrol.
In the dietary supplement and nutraceutical literature, leucoanthocyanidins are frequently encountered as components of, or are used interchangeably with, the broader class called proanthocyanidins (also known as oligomeric proanthocyanidins, or OPCs) and condensed tannins. Alternative names and synonym designations appearing in clinical and commercial contexts include: condensed tannins, oligomeric proanthocyanidins (OPCs), procyanidin oligomers, procyanodolic oligomers (PCOs), and oligomeric procyanidins. Leucoanthocyanidins are monomeric units of proanthocyanidins (condensed tannins), which form through polymerization, and are closely related to flavan-3-ols like catechins via reduction reactions catalyzed by enzymes such as leucoanthocyanidin reductase (LAR).
Leucoanthocyanidins are a class of colorless flavonoid compounds, specifically flavan-3,4-diols, that function as key intermediates in the plant flavonoid biosynthetic pathway, serving as precursors to both anthocyanins and proanthocyanidins (condensed tannins). These molecules possess a C6–C3–C6 carbon skeleton typical of flavonoids, with hydroxyl groups at the 3 and 4 positions of the C ring, enabling their conversion to colored anthocyanidins under acidic conditions or enzymatic catalysis.
Proanthocyanidins — the polymeric forms derived from leucoanthocyanidin monomers — are oligomeric or even polymeric natural substances of a molecular weight ranging from around 500 to over 3,000, which are formally based on simple flavan or flavanol monomers such as (+)-catechin or (−)-epicatechin. The name "proanthocyanidin" reflects the fact that these oligomeric structures can be broken down chemically to form intensively colored anthocyanidins; proanthocyanidins may thus be considered as precursors of anthocyanidins.
Proanthocyanidins — the polymeric condensation products of leucoanthocyanidin monomers — are naturally occurring polyphenolic compounds abundant in many vegetables, plant skins (rind/bark), seeds, flowers, fruits, and nuts. Plants known to be rich sources include grape seeds, pine bark, cocoa, cranberries, and apples.
Leucoanthocyanins can be found in Anadenanthera peregrina and in several species of Nepenthes, including N. burbidgeae, N. muluensis, N. rajah, N. tentaculata, and N. × alisaputrana. Leucocyanidin is a natural product found in Cassia roxburghii, Koenigia coriaria, and Euphorbia hirta. Leucoanthocyanidins are also pivotal intermediates in grape (Vitis vinifera) berry biosynthesis and accumulate transiently in many other fruits during ripening.
The most common proanthocyanidins in food are procyanidins with a 3′,4′-dihydroxy substitution on the B ring and prodelphinidins with a 3′,4′,5′-trihydroxy substitution. Procyanidins or mixed procyanidins/prodelphinidins are most common in food.
Leucoanthocyanidins and their proanthocyanidin condensates are commercially available in a variety of standardized extract forms:
Commercially, these preparations are sold as capsules, tablets, liquid extracts, and standardized powders, typically standardized by their proanthocyanidin or OPC content. Two commercial products extracted from pine trees growing on the west coast of France — Pycnogenol® and Flavangenol® — have been widely studied in vitro and in vivo. While Flavangenol® is obtained by hot water extraction, Pycnogenol® is extracted with water and alcohol.
Tannins — the broader polyphenolic class containing condensed tannins and leucoanthocyanidins — are polyphenolic compounds historically utilized in textile and adhesive industries, but also in traditional human and animal medicines or foodstuffs. Since the 20th century, advances in analytical chemistry allowed disclosure of their chemical nature.
Tannins are ubiquitously present in barks, seeds, or fruit peels of many vegetable species, but also in brown algae. Plant barks and seed coats rich in condensed tannins and leucoanthocyanidins were widely employed by traditional healers in Europe, Asia, and the Americas, long before the identity of the active compounds was established. Historically, these compounds have played a significant role in traditional medicine, valued for their potent antioxidant and anti-inflammatory properties. Folk remedies across Europe and Asia utilized leucoanthocyanin-rich extracts to address a range of ailments, from improving cardiovascular health and reducing capillary fragility to supporting wound healing and combating infections.
Leather tanning has been used for centuries, even millennia, by immersing skins in water where special barks or woods containing tannin have been added. Up to a full year was necessary for leather to be produced in such a manner. The astringent properties of condensed tannin-rich plant materials were simultaneously recognized for medicinal applications — particularly for wound sealing, treating oral infections, gastrointestinal disturbances, and inflammatory conditions of the skin.
Pine bark, a rich source of proanthocyanidins and leucoanthocyanidins, has a long history of use. Pine bark has been used as a foodstuff for thousands of years in human history. Indigenous peoples of North America used infusions of pine bark (notably from Pinus strobus) to treat scurvy, inflammation, and circulatory complaints — uses later validated by European explorers in the 16th century. Similarly, in parts of Asia, pine bark decoctions were employed in traditional medicine for inflammatory and vascular conditions.
The term "leucoanthocyanin" first appeared in 1920 in a paper by Otto Rosenheim describing such compounds in plant material. This represented the beginning of formal scientific characterization, building on earlier 19th-century work on plant polyphenols.
Albert Szent-Györgyi, a 1937 Nobel Prize winner, discovered flavonoids while working on the segregation of vitamin C, terming them "vitamin P." Subsequently, Professor Jacques Masquelier postulated that because pine bark exhibited ascorbate-like effects, it must contain vitamin C along with flavonoids, which he designated as "pycnogenols" — a term no longer used by the scientific community except as a trademark for proanthocyanidins extracted from French maritime pine bark. Masquelier improved and patented a technique to extract oligomeric grape seed proanthocyanidins in 1947, and observed that the bioflavonoids derived from grape seeds appeared to be superior in both concentration and antioxidant effect to those from pine bark.
Masquelier's research placed leucoanthocyanidin-containing extracts firmly within the emerging field of vascular protective nutraceuticals. In the early 20th century, French researcher Jacques Masquelier isolated proanthocyanidins from pine bark and grape seeds, further confirming their efficacy in supporting vascular health. Since then, leucoanthocyanins have been widely recognized for their ability to protect against oxidative stress, strengthen blood vessels, and promote skin health.
In biosynthesis, leucoanthocyanidins are generated from dihydroflavonols by the enzyme dihydroflavonol 4-reductase (DFR), marking a branch point in the flavonoid pathway shared with anthocyanin and flavonol production. Specifically, dihydroflavonols (dihydrokaempferol, dihydroquercetin, and dihydromyricetin) are reduced to flavan-3,4-diols/leucoanthocyanidins (leucopelargonidin, leucocyanidin, or leucodelphinidin, respectively) by dihydroflavonol 4-reductase (DFR) in the course of anthocyanidin and proanthocyanidin biosynthesis.
Once formed, leucoanthocyanidins occupy a pivotal branch point: leucoanthocyanidin reductase (LAR) and anthocyanidin reductase (ANR) catalyze the final reactions in the proanthocyanidin (PA) biosynthetic pathway; LAR converts leucoanthocyanidin (flavan-3,4-diols) to catechin, whereas ANR catalyzes the synthesis of epicatechin from anthocyanidin. PA biosynthesis shares common steps with flavonols and anthocyanins, and their branch point is at the biosynthesis of leucoanthocyanidin.
Leucoanthocyanidins can be further catalyzed to produce anthocyanidins by the oxygenation reaction of anthocyanidin synthase (ANS) or leucoanthocyanidin dioxygenase (LDOX). Leucoanthocyanidin dioxygenase uses flavan-3,4-diols to produce 3-hydroxyanthocyanidins. The gene encoding the enzyme (PpLDOX) has been identified in peach and expression has been studied in Vitis vinifera.
The biosynthesis of the proanthocyanidins is believed to proceed by addition of an electrophilic extension unit derived from a flavan-3,4-diol or a flavan-3-ol to a nucleophilic starter unit, most likely a flavan-3-ol, with sequential addition of further chain-extension units. Proanthocyanidins (PAs) consist of a mixture of flavan-3-ol units and flavan-3,4-diols (leucoanthocyanidins) in complicated ways.
Based on the interflavanic linkages, the subunits linked by C4–C8 and/or C4–C6 bonds are known as B-type PAs, and those with additional C2–O–C7 or C2–O–C5 bond in the structure are classified into A-type PAs. The A-type linkage is of particular functional importance in the case of cranberry proanthocyanidins (see Section 5.3 below).
The biological activity attributed to leucoanthocyanidin-rich preparations derives from a spectrum of related compounds present in the whole extract. In grape seed extract, the preparation is mainly composed of oligomeric proanthocyanidins, with a low amount (5–10%) of monomeric procyanidins (catechin and epicatechin). Pine bark extract contains 80%–85% proanthocyanidins, the monomers catechin and taxifolin (5%), and phenolic acids, including derivatives of benzoic and cinnamic acids (2%–4%). Flavangenol® consists of a concentrate of catechin, taxifolin, and proanthocyanidins, with procyanidin B1 as one major component.
The three most important mechanisms of antioxidant action of proanthocyanidins are: free radical scavenging activity, chelation of transition metals, and inhibition of enzymes. Additionally, a protective role of proanthocyanidins against lipid peroxidation and peroxynitrite has been demonstrated.
Accumulation of prooxidants such as reactive oxygen species (ROS) exceeding cellular antioxidant capacity results in oxidative stress (OS), which can damage macromolecules (DNA, lipids, and proteins), organelles (membranes and mitochondria), and whole tissues. OS is implicated in the pathogenesis and exacerbation of many cardiovascular, neurodegenerative, dermatological, and metabolic diseases, both through direct molecular damage and secondary activation of stress-associated signaling pathways.
At the molecular level, in vitro research has demonstrated that proanthocyanidins (PACs) significantly reduce malondialdehyde, a biomarker of lipid peroxidation, and raise antioxidant enzymes SOD2 and GPx via the increase of NRF2/Keap1 ratio. Likewise, PACs decrease the inflammatory agents TNFα and COX2 through abrogation of NF-κB.
Animal studies have provided detailed mechanistic data. In a rodent model, proanthocyanidins from grape seeds at 10–40 mg/kg (intraperitoneal) inhibited carrageenan-induced paw edema in rats and croton oil-induced ear swelling in mice in a dose-dependent manner. At 10 mg/kg, they reduced MDA content in inflamed paws, inhibited beta-NAG and NOS activity, and lowered the content of NO, IL-1β, TNFα, and PGE2 in exudate from edema paws. These findings are from animal studies and do not directly establish equivalent mechanisms or doses in humans.
At the neurological level, preclinical studies investigated spinal pain mechanisms: intrathecal injection of proanthocyanidins inhibited mechanical and thermal pain sensitivity in mice with inflammatory pain induced by Complete Freund's Adjuvant (CFA) injection. Electrophysiological results showed that proanthocyanidins inhibited the frequency of spontaneous excitatory postsynaptic currents without affecting inhibitory postsynaptic currents. The effect may be mediated by their inhibition of phosphorylated activation of the PI3K/Akt/mTOR pathway molecules in dorsal root ganglia neurons. These are animal/preclinical data.
Oligomeric proanthocyanidins from sources such as Pycnogenol from pine bark enhance nitric oxide (NO) production from vascular endothelium in vitro. Nitric oxide-mediated vasodilation is considered one of the key mechanisms by which these compounds may support vascular function. Grape seed proanthocyanidin extract (GSPE, 0.1% level) has been shown to reduce atherosclerosis in cholesterol-fed rabbits by 30%–50%, probably by inhibiting LDL oxidation, as lipid levels were not altered while malondialdehyde levels in the aorta (an index of lipid oxidation) were reduced by 25%. These are animal data.
To study the in vivo relevancy of proanthocyanidin activities, knowledge of their pharmacokinetic parameters is crucial. Although bioavailability and metabolism data on polyphenols in general and proanthocyanidins in particular are still largely unavailable, the first reports indicate that at least monomers and smaller oligomeric procyanidins are absorbed.
The absorption of the bioactive compounds depends on their chemical characteristics and the formulation of the product consumed. Studies indicate that PACs, due to their large molecular size and complexity, have limited oral bioavailability. However, small amounts that are absorbed through the gastrointestinal tract can still exert systemic effects. While PACs can prevent the adhesion of pathogenic E. coli to uroepithelial cells under in vitro conditions, recent research indicates limited absorption of PACs ingested by humans due to metabolism by gut microbiota and low levels of PACs in urine. Further research has shown that a significant amount of phenolic metabolites produced by microbial breakdown of PACs in the gut can be absorbed by the body and excreted through urine.
In vitro studies often use levels of 10–50 μg/mL, which is 10–20 times higher than what might be achieved in human studies. This gap between concentrations tested in cell and animal experiments and those realistically attainable in human tissues is a recurring limitation in interpreting the preclinical literature.
OPCs may enhance insulin sensitivity by reducing oxidative stress in peripheral tissues, which is known to impair insulin receptor signalling. Some laboratory studies also suggest that proanthocyanidins can inhibit certain digestive enzymes — including alpha-amylase and alpha-glucosidase — thereby slowing the breakdown and absorption of dietary carbohydrates. These mechanisms are largely based on preclinical data; their relevance to human glycaemic control has not been fully established.
Evidence summary: Preliminary to moderate; human RCT data available but limited in size and quality.
Previous clinical studies in pre- and mildly hypertensive subjects showed that the standardized grape seed extract Enovita® from Vitis vinifera L. seeds, supplemented for a four-month period, produced beneficial cardiovascular effects. A notable clinical study enrolled patients with atherosclerosis: 287 patients diagnosed with asymptomatic carotid plaques or abnormal plaque-free carotid intima-media thickness (CIMT) were randomly assigned to the GSPE group (n = 146) or control group (n = 141). Patients in the GSPE group received GSPE 200 mg per day orally, while patients in the control group were only enrolled in a lifestyle intervention program. Carotid ultrasound examination was performed at baseline and at 6, 12, and 24 months. Mean maximum CIMT, plaque score, echogenicity of plaques, and ischemic vascular events were recorded. After treatment, GSPE resulted in significant reduction in MMCIMT progression. This was a randomized study, but the control arm received only lifestyle intervention rather than a matched placebo, which limits interpretation.
Extensive research conducted with several formulations of pine bark extracts has established its safety and tolerability for human consumption. More recent research has focused primarily on clinical efficacy and growing data suggest an array of cardiovascular benefits. However, the studies published to date on the clinical efficacy of pine bark extracts all have outstanding methodological limitations — for example, lack of a control group, lack of randomization, lack of or inadequate blinding, insufficient statistical power, and incorrect statistical analyses.
Studies suggest a possible role in cardiovascular disease. However, large quality clinical trials are lacking to recommend use for any indication.
Evidence summary: Well-established in vitro and animal models; human evidence of biomarker change is present but clinical significance remains to be determined.
Numerous in vitro and in vivo studies have demonstrated myriad effects potentially beneficial to human health, such as antioxidation, anti-inflammation, immunomodulation, DNA repair, and antitumor activity. In human studies, proanthocyanidin-rich extracts have been shown to reduce circulating oxidative stress biomarkers such as oxidized LDL. In hypercholesterolemic subjects, a human clinical trial was conducted on hypercholesterolemic subjects; GSPE supplementation significantly reduced oxidized LDL, a biomarker of cardiovascular disease risk. The broader clinical significance of these biomarker changes for hard cardiovascular outcomes remains unconfirmed.
Evidence summary: Moderate; supported by meta-analyses of RCTs, though dose thresholds are debated and bioavailability of PACs in urine is uncertain.
Cranberries contain proanthocyanidins (PACs), which inhibit the adherence of p-fimbriated Escherichia coli to the urothelial cells lining the bladder. Cranberry products have been used widely for several decades to prevent urinary tract infections (UTIs). The most structurally relevant compounds are A-type proanthocyanidins: among the different polyphenols found in cranberries, proanthocyanidins possess special relevance for their actions against UTI bacteria. PACs are oligomers composed of flavan-3-ol monomers polymerized by interflavan bonds that can be described as either "A-type" (showing an additional C2–O–C7 ether bond) or "B-type" (showing a single C4–C6 or C4–C8 bond). The A-type linkages present in cranberry PAC are known to inhibit the adhesion of P-fimbriated Escherichia coli.
A 2024 meta-analysis of RCTs found that ten RCTs that matched the requirements were included, and the results showed that when the daily intake of PACs was at least 36 mg, the risk of UTIs was reduced by 18% (RR = 0.82, 95% CI = 0.69–0.98, p = 0.03). However, there is currently no established regimen for what PAC dose to use and no formal regulation by health authorities of cranberry products. In particular, the dose suggested may not be included on the package. The mechanistic explanation remains contested: although PACs have been considered the primary reason for cranberries' UTI prevention properties in recent decades, the specific mechanisms by which they operate are still being researched. While PACs can prevent the adhesion of pathogenic E. coli to uroepithelial cells under in vitro conditions, this finding has been challenged by research indicating limited absorption of PACs ingested by humans due to metabolism by gut microbiota and low levels of PACs in urine.
Evidence summary: Preliminary; small RCTs suggest modest effects on glucose and lipid biomarkers, but evidence is insufficient for clinical recommendations.
Grape seed extract may modestly reduce HbA1c and fasting blood glucose in some small clinical trials, but evidence is insufficient to recommend it as a treatment for type 2 diabetes under current guidance. Grape seed extract (GSE) is rich in oligomeric proanthocyanidins (OPCs), polyphenolic compounds with antioxidant and anti-inflammatory properties. Some small RCTs report modest reductions in HbA1c and fasting glucose with GSE, but study quality is generally low to moderate and sample sizes are small.
Diabetes can cause the inflammation of vasculature and endothelial dysfunction, which grape seed proanthocyanidin extracts can attenuate. Proanthocyanidin could heal myocardial damage via antioxidant and anti-inflammatory effects. These findings draw largely from animal and in vitro studies.
Evidence summary: Promising preclinical data; some preliminary clinical evidence for skin applications.
Proanthocyanidins (PACs), a subclass of polyphenolic compounds renowned for their anti-inflammatory and antioxidant properties, are promising candidates for dermatologic applications. A review synthesizing 25 years of research on biomolecular mechanisms, pharmacological effects, and phytochemical aspects of PACs in the context of treating inflammatory-related skin problems highlights pro-regenerative, pro-angiogenic, antioxidative, and anti-inflammatory effects of PACs in accelerating wound closure. Preclinical data suggest their potent ability to mitigate chronic skin inflammatory disorders, including psoriasis and atopic dermatitis.
Among studies on Flavangenol®, the extract showed antiphotoaging and anticarcinogenetic activities in melanin-possessing hairless mice, which may be due to a scavenging effect on ROS, inhibiting Ki-67, 8-OHdG, and VEGF expression. These are animal data.
Evidence summary: Largely preclinical (animal and cell-based); human clinical evidence is very limited.
Pine bark extract showed antioxidant, anti-inflammatory, immunostimulant, cardioprotective, and neuroprotective effects in preclinical studies. The precise mechanisms of the important physiologic functions of pine bark extract components remain to be elucidated, but there is evidently great potential for the identification and development of novel antioxidant, anti-inflammatory, cardiovascular, neuroprotective, and anticancer medicines. Animal ischemia models show that pine bark proanthocyanidins can reduce neuronal loss following cerebral ischemia, but these findings have not been replicated in human trials.
Many beneficial properties in cardiovascular, cancer, and neurological diseases as antioxidant, immunomodulatory, antidiabetic, cardio, and neuroprotective agents have long been described in the scientific literature for proanthocyanidins. Despite this, robust human clinical trial evidence specifically addressing cognitive outcomes for leucoanthocyanidin/proanthocyanidin supplements remains sparse.
Evidence summary: Primarily in vitro and animal; no established clinical evidence in humans.
A proanthocyanidin-rich fraction of Stryphnodendron adstringens, when tested on HeLa and SiHa cells via MTT assay, exerted oxidative stress and mitochondrial damage, triggering apoptosis. However, this cancer cell inhibitory effect could be a case of osmotic alterations. The lack of immune surveillance in the in vitro test medium could have led to the death of the cancer cells, which is not likely in a cancerous body.
Literature on health aspects of proanthocyanidins in cancer is ample, but the mechanism cited is often confounding. In some studies, oxidative stress elimination of proanthocyanidin is cited as the reason of health benefit, whereas in some studies, oxidative stress induction is cited as the reason of health benefit. These contradictions highlight the need for careful interpretation of in vitro anticancer data.
Evidence summary: Preclinical (animal) only.
Proanthocyanidins have been reported to exert anti-inflammatory pain-alleviating effects. However, the mechanism by which proanthocyanidins relieve inflammatory pain in the central nervous system is unclear. Research in rodent models indicates spinal mechanisms via PI3K/Akt/mTOR inhibition, but clinical translation has not been demonstrated in published human studies.
Evidence summary: Emerging; predominantly preclinical and early-phase human studies.
Despite the limited number of studies and the difficulties with human intervention trials, there is a consensus that grape seed proanthocyanidins can contribute to modulating microbial ecology and gut microbiota with human health benefits, and thus show promise to use as a nutraceutical. Additional research is required to fully understand the complex relationship between gut microbiota and grape seed proanthocyanidins to substantiate any potential health benefit claims.
Leucoanthocyanidin-containing preparations are administered in a variety of forms and dosages. The following reflect only dosages as reported in published clinical or toxicological studies:
Although toxicological data for pine bark extracts are limited, no serious adverse effects have been reported. Pine bark extracts may therefore have potential as nutraceuticals and pharmaceuticals and should be safe for use as food ingredients.
No human toxicity has been reported for grape seed. A safety evaluation of proanthocyanidin from grape seeds administered orally to mice demonstrated no evidence of toxicity and mutagenicity at acute doses of 2 and 4 g/kg. No evidence of acute oral toxicity at dosages of 2 and 4 g/kg, and no evidence of mutagenicity in the above tests was found. Administration of GSE as a dietary admixture at levels of 0.02, 0.2, and 2% (w/w) to the rats for 90 days did not induce noticeable signs of toxicity.
Clinical trials have generally reported that grape seed extract is well tolerated.
Grape seed is contraindicated in individuals with known hypersensitivity to grape products. Information regarding safety and efficacy in pregnancy and lactation is lacking.
CYP-450 enzyme-mediated herbal drug interactions are possible; caution should be exercised. Grape seed may increase the serum concentration of dextromethorphan.
GSE has antiplatelet properties and may interact with anticoagulants (warfarin, DOACs) and antiplatelet drugs, increasing bleeding risk. There is a theoretical risk of hypoglycaemia when GSE is combined with insulin or sulphonylureas.
The probable side effects of long-term elevated proanthocyanidin intake — including preventing nutrient consumption, interacting with other food compounds, inhibiting digestive enzymes, and interacting with drugs — should be investigated. More systematic toxicological studies should be administered, given that in the "real world" proanthocyanidins are used as a supplementary element in various food preparations.
The protein-binding capacity of condensed tannins — a property shared by leucoanthocyanidins and their proanthocyanidin condensates — is well established. By their nature and abundance of hydroxyl radicals, tannins are highly hydrophilic molecules, soluble in aqueous solvents and exhibiting a high tendency to stably bond with proteins and carbohydrates. This protein-binding capacity is relevant to potential interactions with dietary proteins and digestive enzymes at high intakes.
A recurring challenge in the field is the heterogeneity between studies: different source plants, different extraction methods, varying degrees of polymerization, and variable standardization make it difficult to compare results across trials. Composition of commercial grape seed preparations is highly variable. Additionally, literature on health aspects of proanthocyanidins is ample, but the mechanism cited is often confounding. In some studies, oxidative stress elimination of proanthocyanidin is cited as the reason of health benefit, whereas in some studies, oxidative stress induction is cited as the reason of health benefit.
The gap between preclinical and clinical evidence is substantial. In vitro studies often use levels of 10–50 μg/mL, which is 10–20 times higher than what might be achieved in human studies. The studies published to date on the clinical efficacy of pine bark extracts all have outstanding methodological limitations, including lack of a control group, lack of randomization, lack of or inadequate blinding, insufficient statistical power, and incorrect statistical analyses. Large, well-powered, placebo-controlled, double-blind RCTs are needed across all proposed indications.
Health conditions that Leucoanthocyanidins may help support.
Body systems that Leucoanthocyanidins may help support.
Go back